Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective. [PDF]
Background/Objectives: Obesity is a chronic, multifactorial condition driven by complex neuroendocrine and metabolic pathways that limit the long-term success of lifestyle interventions.
Ahmad I +9 more
europepmc +2 more sources
Incretin-Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor-Network Pharmacology and Phenotype-Based Clinical Positioning. [PDF]
ABSTRACT Aims Incretin‐based pharmacotherapy was initially developed to improve glucose‐dependent insulin secretion and glycaemic control in type 2 diabetes, but its clinical interpretation has expanded substantially with cardiovascular outcome trials, kidney outcome data, obesity studies and next‐generation polyagonist development.
Sztanek F +3 more
europepmc +2 more sources
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Background: Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved to treat type 2 diabetes and obesity. They elicit robust improvements in glycemic control and weight loss, combined with cardioprotection in individuals at risk of or with pre ...
Laurie L. Baggio, Daniel J. Drucker
doaj +1 more source
Molecularly guided pharmacotherapy for obesity: emerging targets, clinical efficacy, and personalized therapeutic approaches. [PDF]
Obesity is a complex, chronic disease whose aetiology is complex and highly variable, and is linked to a network of neural, endocrine, adipose, genetic, epigenetic and metabolic pathways.
Mao J, Hu R.
europepmc +2 more sources
The calcitonin and amylin receptors (CTR and AMY receptors) are the drug targets for osteoporosis and diabetes treatment, respectively. Salmon calcitonin (sCT) and pramlintide were developed as peptide drugs that activate these receptors.
Sangmin Lee
doaj +1 more source
Determinants of variable response to GLP-1 receptor agonists: A mechanism-informed framework for precision treatment of obesity. [PDF]
Introduction: The management of obesity changed significantly with the introduction of glucagon-like peptide-1 receptor agonists (GLP-1RAs). However, considerable interindividual variability in weight-loss response remains, and its determinants are ...
Ghosal S.
europepmc +2 more sources
Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat
The hormones amylin and calcitonin interact with receptors within the same family to exert their effects on the human organism. Calcitonin, derived from thyroid C cells, is known for its inhibitory effect on osteoclasts.
David S. Mathiesen +10 more
doaj +1 more source
Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. [PDF]
Obesity affects over 2 billion adults globally, with projections indicating that nearly two-thirds of adults will be affected by 2050. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed obesity treatment, achieving weight loss ...
Lempesis IG, Dalamaga M.
europepmc +2 more sources
Alcohol use disorder (AUD) contributes substantially to global morbidity and mortality. Given the heterogenicity of this brain disease, available pharmacological treatments only display efficacy in sub-set of individuals.
Maximilian Tufvesson-Alm +2 more
doaj +1 more source
CiD agonists: Circular DNA-based agonists for the fine-tuning of receptor signaling [PDF]
Receptor dimerization geometry plays a significant role in signal transduction induced by growth factors and cytokines. A chemical strategy capable of controlling dimerization geometry provides a means for studying receptor activation mechanisms and ...
Momoko , Akiyama +9 more
core +2 more sources

